U.S. FDA Schedules COVID-19 Vaccine 2023-2024 Selection Meeting

The U.S. Food and Drug Administration (FDA) announced on May 4, 2023, a future meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC).

On June 15, 2023, the VRBPAC will meet in an open session to discuss and make recommendations on selecting strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign.

This discussion will include consideration of the vaccine composition for fall to winter 2023-2024. And it will be open for viewing by the public and will be hosted at this YouTube link. 

The Docket Number is FDA-2023-N-1553.

The VRBPAC provides independent expert advice to the FDA on broad scientific topics or certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. 

The FDA currently endorses mRNA and protein-based COVID-19 vaccines and monoclonal antibody therapies.

On April 4, 2023, InflaRx N.V.'s Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, was granted an Emergency Use Authorization by the FDA.

Recently, the World Health Organization announced the ending of its pandemic declaration for COVID-19 since it is now an established and ongoing health issue that no longer constitutes a public health emergency of international concern.